{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:12:07Z","timestamp":1793913127185,"version":"4.8.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00228-025-03850-6","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T13:37:48Z","timestamp":1748525868000},"page":"1103-1117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Tegoprazan: a novel, highly selective, and potent potassium-competitive acid blocker (P-CAB)"],"prefix":"10.1007","volume":"81","author":[{"given":"Wenlu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiza Sidra","family":"Yaseen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoji","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Zia","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guorong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Naveed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz Muhammad","family":"Zubair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannat","family":"Bibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"1","key":"3850_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5056\/jnm18139","volume":"25","author":"H, M., & H, S.","year":"2019","unstructured":"H, M., & H, S. (2019) Role of acid suppression in acid-related diseases: proton pump inhibitor and potassium-competitive acid blocker. Neurogastroenterol Motil 25(1):6\u201314. https:\/\/doi.org\/10.5056\/jnm18139","journal-title":"Neurogastroenterol Motil"},{"issue":"2","key":"3850_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/nrd1010","volume":"2","author":"L Olbe","year":"2003","unstructured":"Olbe L, Carlsson E, P., L. (2003) A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2(2):132\u2013139. https:\/\/doi.org\/10.1038\/nrd1010","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"3850_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1113\/jphysiol.1909.sp001303","volume":"38","author":"JS Edkins","year":"1909","unstructured":"Edkins JS, Tweedy M (1909) The natural channels of absorption evoking the chemical mechanism of gastric secretion. J Physiol 38(4):263\u2013267","journal-title":"J Physiol"},{"issue":"Suppl 1","key":"3850_CR4","first-page":"493S","volume":"1","author":"W Schunack","year":"1987","unstructured":"Schunack W (1987) What are the differences between the H2-receptor antagonists? Aliment Pharmacol Ther 1(Suppl 1):493S-503S","journal-title":"Aliment Pharmacol Ther"},{"issue":"5802","key":"3850_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/290159a0","volume":"290","author":"E Fellenius","year":"1981","unstructured":"Fellenius E, Berglindh T, Sachs G, Olbe L, Elander B, Sj\u00f6strand SE, Wallmark B (1981) Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase. Nature 290(5802):159\u2013161","journal-title":"Nature"},{"issue":"49","key":"3850_CR6","doi-asserted-by":"publisher","first-page":"16321","DOI":"10.1021\/bi051342q","volume":"44","author":"JM Shin","year":"2005","unstructured":"Shin JM, Grundler G, Senn-Bilfinger J, Simon WA, Sachs G (2005) Functional 2134 consequences of the oligomeric form of the membrane-bound gastric H. K-ATPase Biochemistry 44(49):16321\u201316332","journal-title":"K-ATPase Biochemistry"},{"issue":"5","key":"3850_CR7","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1053\/gast.2002.36593","volume":"123","author":"JM Shin","year":"2002","unstructured":"Shin JM, Sachs G (2002) Restoration of acid secretion following treatment with proton 2143 pump inhibitors. Gastroenterology 123(5):1588\u20131597. https:\/\/doi.org\/10.1053\/gast.2002.36593","journal-title":"Gastroenterology"},{"issue":"2","key":"3850_CR8","doi-asserted-by":"publisher","first-page":"S226","DOI":"10.1097\/MCG.0b013e31803233b7","volume":"41","author":"O Vagin","year":"2007","unstructured":"Vagin O, Sachs G, Yakubov I, Munson K, Lambrecht N, Shin JM (2007) The gastric H, K ATPase as a drug target: past, present, and future. Clin Gastroenterol 41(2):S226\u2013S242. https:\/\/doi.org\/10.1097\/MCG.0b013e31803233b7","journal-title":"Clin Gastroenterol"},{"issue":"1","key":"3850_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/nyas.14473","volume":"1482","author":"C Scarpignato","year":"2020","unstructured":"Scarpignato C, Hongo M, Wu JCY, Lottrup C, Lazarescu A, Stein E, Hunt RH (2020) Pharmacologic treatment of GERD: where we are now, and where are we going? Ann N Y Acad Sci 1482(1):193\u2013212. https:\/\/doi.org\/10.1111\/nyas.14473","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"3850_CR10","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1592\/phco.23.4.460.32128","volume":"23","author":"E Chong","year":"2003","unstructured":"Chong E, MH., E. (2003) Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 23(4):460\u2013471","journal-title":"Pharmacotherapy"},{"issue":"4","key":"3850_CR11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s10620-006-9156-7","volume":"52","author":"DA Peura","year":"2007","unstructured":"Peura DA, Gudmundson J, Siepman N, Pilmer BL, Freston J (2007) Proton pump inhibitors: effective first-line treatment for management of dyspepsia. Dig Dis Sci 52(4):983\u2013987","journal-title":"Dig Dis Sci"},{"issue":"1","key":"3850_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00228-008-0576-5","volume":"65","author":"J Kirchheiner","year":"2009","unstructured":"Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, J., B. (2009) Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol 65(1):19\u201331. https:\/\/doi.org\/10.1007\/s00228-008-0576-5","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"3850_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2133\/dmpk.20.153","volume":"20","author":"T Furuta","year":"2005","unstructured":"Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T (2005) Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 20(3):153\u2013167","journal-title":"Drug Metab Pharmacokinet"},{"key":"3850_CR14","doi-asserted-by":"crossref","unstructured":"Graham DY, & MP., D. (2018). Graham DY, Dore MP. Update on use of vonoprazan a competitive acid blocker (P-CAB). Gastroenteroloy. 2018;154462\u2013466. Gastroenteroloy, 154(3), 462\u2013466.","DOI":"10.1053\/j.gastro.2018.01.018"},{"issue":"7","key":"3850_CR15","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H, Sakurai Y, Nishimura A (2015) Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438(vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 41(7):636\u2013648. https:\/\/doi.org\/10.1111\/apt.13121","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3850_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/apt.14818","volume":"48","author":"J Sunwoo","year":"2018","unstructured":"Sunwoo J, Oh J, Moon SJ (2018) Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 48(2):206\u2013218. https:\/\/doi.org\/10.1111\/apt.14818","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"3850_CR17","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/apt.13588","volume":"43","author":"T Kagami","year":"2016","unstructured":"Kagami T, Sahara S, Ichikawa H, Uotani T (2016) Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther 43(10):1048\u20131059. https:\/\/doi.org\/10.1111\/apt.13588","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"3850_CR18","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1002\/jgh.16017","volume":"37","author":"AF yam","year":"2022","unstructured":"yam AF, Lee YY, Simadibrata FM (2022) A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: a systematic review and meta-analysis. Gastroenterol Hepatol 37(12):2217\u20132228. https:\/\/doi.org\/10.1002\/jgh.16017","journal-title":"Gastroenterol Hepatol"},{"key":"3850_CR19","doi-asserted-by":"publisher","unstructured":"Sugano, K. (2018). Vonoprazan fumarate, a novel potassiumcompetitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol, 9(11). https:\/\/doi.org\/10.1177\/1756283X17745776","DOI":"10.1177\/1756283X17745776"},{"issue":"7","key":"3850_CR20","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/apt.15185","volume":"49","author":"Kwang Jae Lee","year":"2019","unstructured":"Lee Kwang Jae, Son Byoung Kwan, Kim Gwang Ha (2019) Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis. Aliment Pharmacol Ther 49(7):864\u2013872. https:\/\/doi.org\/10.1111\/apt.15185","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"3850_CR21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1358\/dot.2020.56.11.3202811","volume":"56","author":"J Mermelstein","year":"2020","unstructured":"Mermelstein J, Mermelstein AC, MM C (2020) Tegoprazan to treat gastroesophageal reflux disease. Drugs Today (Barc) 56(11):715\u2013721","journal-title":"Drugs Today (Barc)"},{"issue":"5","key":"3850_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/apt.15865","volume":"52","author":"YK Cho","year":"2020","unstructured":"Cho YK, Choi MG, Choi SC, KM L (2020) Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer. Aliment Pharmacol Ther 52(5):789\u2013797. https:\/\/doi.org\/10.1111\/apt.15865","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3850_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1152\/physrev.00016.2019","volume":"100","author":"AC Engevik","year":"2020","unstructured":"Engevik AC, Kaji I, JR, G. (2020) The physiology of the gastric parietal cell. Physiol Rev 100(2):573\u2013602","journal-title":"Physiol Rev"},{"issue":"6","key":"3850_CR24","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/MOG.0000000000000392","volume":"33","author":"ML Schubert","year":"2017","unstructured":"Schubert ML (2017) Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. Curr Opin Gastroenterol 33(6):430\u2013438. https:\/\/doi.org\/10.1097\/MOG.0000000000000392","journal-title":"Curr Opin Gastroenterol"},{"issue":"10","key":"3850_CR25","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.3390\/pharmaceutics14102043","volume":"14","author":"J Srebro","year":"2022","unstructured":"Srebro J, Brniak W, Mendyk A (2022) Formulation of dosage forms with proton pump inhibitors: state of the art, challenges and future perspectives. Pharmaceutics 14(10):2043. https:\/\/doi.org\/10.3390\/pharmaceutics14102043","journal-title":"Pharmaceutics"},{"issue":"8","key":"3850_CR26","first-page":"1311","volume":"74","author":"K Haruma","year":"2016","unstructured":"Haruma K, Suehiro M, Kawamoto H (2016) Potassium-competitive acid blocker. Nihon Rinsho 74(8):1311\u20131315","journal-title":"Nihon Rinsho"},{"issue":"28","key":"3850_CR27","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.3748\/wjg.v28.i28.3608","volume":"28","author":"W Leowattana","year":"2022","unstructured":"Leowattana W, Leowattana T (2022) Potassium-competitive acid blockers and gastroesophageal reflux disease. World J Gastroenterol 28(28):3535\u20133752","journal-title":"World J Gastroenterol"},{"issue":"7","key":"3850_CR28","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/apt.16295","volume":"53","author":"Y Abdel-Aziz","year":"2021","unstructured":"Abdel-Aziz Y, Metz DC, CW H (2021) Review article: potassium-competitive acid blockers for the treatment of acid-related disorders. Aliment Pharmacol Ther 53(7):794\u2013809. https:\/\/doi.org\/10.1111\/apt.16295","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"3850_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5114\/pg.2022.116673","volume":"18","author":"G Domingues","year":"2023","unstructured":"Domingues G, Chinzon D, Joaquim Prado P, Moraes-Filho JT, Senra P, M., & , S. Z. (2023) Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review. Prz Gastroenterol 18(1):47\u201355. https:\/\/doi.org\/10.5114\/pg.2022.116673","journal-title":"Prz Gastroenterol"},{"issue":"6","key":"3850_CR30","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/1756283X16668093","volume":"9","author":"Y Akazawa","year":"2016","unstructured":"Akazawa Y, Fukuda D, Fukuda Y (2016) Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence. Therap Adv Gastroenterol 9(6):845\u2013852. https:\/\/doi.org\/10.1177\/1756283X16668093","journal-title":"Therap Adv Gastroenterol"},{"key":"3850_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-070752","author":"D Jenkins","year":"2023","unstructured":"Jenkins D, Modolell I (2023) Proton pump inhibitors. BMJ. https:\/\/doi.org\/10.1136\/bmj-2022-070752","journal-title":"BMJ"},{"issue":"5","key":"3850_CR32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/17474124.2021.1984878","volume":"16","author":"V Savarino","year":"2022","unstructured":"Savarino V, Antonioli L, Fornai M, Marabotto E, Demarzo MG, Zingone F, Matteo. (2022) An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Rev Gastroenterol Hepatol 16(5):401\u2013410. https:\/\/doi.org\/10.1080\/17474124.2021.1984878","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"2","key":"3850_CR33","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1124\/jpet.117.244202","volume":"364","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Take Y (2018) Tegoprazan, a novel potassium-competitive acid blocker to control gastric acid secretion and motility. J Pharmacol Exp Ther 364(2):275\u2013286. https:\/\/doi.org\/10.1124\/jpet.117.244202","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"3850_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40261-020-00986-4","volume":"41","author":"J He","year":"2021","unstructured":"He J, Cao G, Jicheng Yu, Wang J, Cheng N (2021) Safety, tolerability and pharmacokinetics of single ascending and multiple oral doses of tegoprazan in healthy Chinese subjects. Clin Drug Investig 41(1):89\u201397. https:\/\/doi.org\/10.1007\/s40261-020-00986-4","journal-title":"Clin Drug Investig"},{"issue":"7","key":"3850_CR35","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/apt.15438","volume":"50","author":"S Han","year":"2019","unstructured":"Han S, Choi HY, Kim YH, Nam JY (2019) Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 50(7):751\u2013759. https:\/\/doi.org\/10.1111\/apt.15438","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"3850_CR36","doi-asserted-by":"publisher","first-page":"410","DOI":"10.5414\/CP204378","volume":"61","author":"JA Lee","year":"2023","unstructured":"Lee JA, Goak IS, Lee J, Kim B, Moon SJ, Kwak YJ, Kim MG (2023) Evaluation of the comparative pharmacokinetic properties of a new orally disintegrating tablet of tegoprazan in healthy Korean subjects. Int J Clin Pharmacol Ther 61(9):410\u2013420. https:\/\/doi.org\/10.5414\/CP204378","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"4","key":"3850_CR37","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.clinthera.2021.01.026","volume":"43","author":"J-Y Jeon","year":"2021","unstructured":"Jeon J-Y, Kim S-Y, Moon SJ, Kyeongmin Oh, Lee J, Kim B, Song GS, Kim M-G (2021) Pharmacokinetic Interactions between tegoprazan and metronidazole\/tetracycline\/bismuth and safety assessment in healthy Korean male subjects. Clin Ther 43(4):722\u2013734. https:\/\/doi.org\/10.1016\/j.clinthera.2021.01.026","journal-title":"Clin Ther"},{"key":"3850_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jpba.2019.03.045","volume":"171","author":"J Kim","year":"2019","unstructured":"Kim J, Kim S, Noh HJ, Ryu SY, SJ K (2019) Simultaneous quantification of tegoprazan and its major metabolite M1 in dog plasma using liquid chromatography-tandem mass. J Pharm Biomed Anal 171:99\u2013103. https:\/\/doi.org\/10.1016\/j.jpba.2019.03.045","journal-title":"J Pharm Biomed Anal"},{"issue":"7","key":"3850_CR39","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/jcph.1805","volume":"61","author":"J-L Ghim","year":"2021","unstructured":"Ghim J-L, Chin MC, Jung J (2021) Pharmacokinetics and pharmacodynamics of tegoprazan coadministered with amoxicillin and clarithromycin in healthy subjects. J Clin Pharmacol 61(7):913\u2013922. https:\/\/doi.org\/10.1002\/jcph.1805","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"3850_CR40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.12793\/tcp.2019.27.2.80","volume":"27","author":"Jun Gi Hwang","year":"2019","unstructured":"Hwang Jun Gi, Yoo Hyounggyoon, Lee Ji Won, Song Geun Seog, Lee SeungHwan, Kim M-G (2019) Comparison of pharmacokinetic characteristics of two Tegoprazan\u00a0(CJ-12420) formulations in healthy male subjects. Transl Clin Pharmacol 27(2):80\u201385. https:\/\/doi.org\/10.12793\/tcp.2019.27.2.80","journal-title":"Transl Clin Pharmacol"},{"issue":"4","key":"3850_CR41","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40262-023-01228-4","volume":"62","author":"E Yang","year":"2023","unstructured":"Yang E, Ji SC, Jang IJ, S, L. (2023) Evaluation of CYP2C19-mediated pharmacokinetic drug interaction of tegoprazan, compared with vonoprazan or esomeprazole. Clin Pharmacokinet 62(4):599\u2013608. https:\/\/doi.org\/10.1007\/s40262-023-01228-4","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3850_CR42","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/cts.12958","volume":"14","author":"DY Yoon","year":"2021","unstructured":"Yoon DY, Sunwoo J, Shin N, Kim AR (2021) Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers. Clin Transl Sci 14(3):934\u2013941. https:\/\/doi.org\/10.1111\/cts.12958","journal-title":"Clin Transl Sci"},{"issue":"9","key":"3850_CR43","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.3390\/pharmaceutics13091489","volume":"13","author":"DY Yoon","year":"2021","unstructured":"Yoon DY, Lee SeungHwan, Jang InJin, Kim M, Lee H, Kim S, Kim B, Song GS, Rhee S (2021) Prediction of drug-drug interaction potential of tegoprazan using physiologically based pharmacokinetic modeling and simulation. Pharmaceutics 13(9):1489. https:\/\/doi.org\/10.3390\/pharmaceutics13091489","journal-title":"Pharmaceutics"},{"issue":"8","key":"3850_CR44","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.clinthera.2021.06.007","volume":"43","author":"S Han","year":"2021","unstructured":"Han S, Choi HY, Kim YH, Nam JY, Kim B, Song GS, Lim HS, KS B (2021) Effect of food on the pharmacokinetics and pharmacodynamics of a single oral dose of tegoprazan. Clin Ther 43(8):1371\u20131380. https:\/\/doi.org\/10.1016\/j.clinthera.2021.06.007","journal-title":"Clin Ther"},{"issue":"10","key":"3850_CR45","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/j.1365-2036.2009.03976.x","volume":"29","author":"A Varro","year":"2009","unstructured":"Varro A, Murugesan SVM, Pritchard DM (2009) Review article: strategies to determine whether hypergastrinaemia is due to Zollinger-Ellison syndrome rather than a more common benign cause. Aliment Pharmacol Ther 29(10):1055\u20131068. https:\/\/doi.org\/10.1111\/j.1365-2036.2009.03976.x","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"3850_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","volume":"11","author":"DS Strand","year":"2017","unstructured":"Strand DS, Kim D, DA, P. (2017) 25 years of proton pump inhibitors: a comprehensive review. Gut Liver 11(1):27\u201337. https:\/\/doi.org\/10.5009\/gnl15502","journal-title":"Gut Liver"},{"issue":"12","key":"3850_CR47","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1111\/apt.16121","volume":"11","author":"J Sunwoo","year":"2020","unstructured":"Sunwoo J, Ji SC, Jaeseong Oh, Ban MS, Nam JY, Kim B, Song GS, Kyung-Sang Yu, Jang I-J, Lee S (2020) Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects. Aliment Pharmacol Ther 11(12):1640\u20131647. https:\/\/doi.org\/10.1111\/apt.16121","journal-title":"Aliment Pharmacol Ther"},{"key":"3850_CR48","doi-asserted-by":"crossref","unstructured":"JG, H. (2002). Review article: gastric acidity--comparison of esomeprazole with other proton pump inhibitors. Aliment Pharmacol Ther, 17(1), 10,15,17,discussion 16.","DOI":"10.1046\/j.1365-2036.17.s1.3.x"},{"key":"3850_CR49","first-page":"459","volume":"16","author":"H Sakai","year":"2016","unstructured":"Sakai H, Fujii T, Takeguchi N (2016) Proton-potassium (H(+)\/K(+)) ATPases: properties and roles in health and diseases. Met Ions Life Sci 16:459\u2013483","journal-title":"Met Ions Life Sci"},{"issue":"5","key":"3850_CR50","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/00041552-199609000-00006","volume":"5","author":"TD DuBose Jr","year":"1996","unstructured":"DuBose TD Jr, Codina J (1996) H, K-ATPase. Curr Opin Nephrol Hypertens 5(5):411\u2013416","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"3850_CR51","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.bcp.2006.09.020","volume":"73","author":"K Gedda","year":"2007","unstructured":"Gedda K, Briving C, Svensson K (2007) Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+, K+-ATPase. Biochem Pharmacol 73(2):198\u2013205. https:\/\/doi.org\/10.1016\/j.bcp.2006.09.020","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"3850_CR52","doi-asserted-by":"publisher","first-page":"6848","DOI":"10.1074\/jbc.274.11.6848","volume":"274","author":"S Asano","year":"1999","unstructured":"Asano S, Matsuda S, Hoshina S, Sakamoto S, Takeguchi N (1999) A chimeric gastric 1190 H+, K+-ATPase inhibitable with both ouabain and SCH 28080. J Biol Chem 274(11):6848\u20136854","journal-title":"J Biol Chem"},{"issue":"14","key":"3850_CR53","doi-asserted-by":"publisher","first-page":"13968","DOI":"10.1074\/jbc.M308934200","volume":"279","author":"S Asano","year":"2004","unstructured":"Asano S, Yoshida A, Yashiro H, Kobayashi Y, Morisato A, Ogawa H, Takeguchi N, Morii M (2004) The cavity structure for docking the K(+)-competitive inhibitors in the gastric 1194 proton pump. J Biol Chem 279(14):13968\u201313975. https:\/\/doi.org\/10.1074\/jbc.M308934200","journal-title":"J Biol Chem"},{"issue":"3","key":"3850_CR54","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1124\/jpet.111.179556","volume":"337","author":"Y Hori","year":"2011","unstructured":"Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M, Inatomi N (2011) A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 337(3):797\u2013804. https:\/\/doi.org\/10.1124\/jpet.111.179556","journal-title":"J Pharmacol Exp Ther"},{"issue":"267","key":"3850_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygcen.2018.05.022","volume":"1","author":"Y Xian","year":"2018","unstructured":"Xian Y, Zhao X, Wang C, Kang C, Ding L, Zhu W, Hang S (2018) Phenylalanine and tryptophan stimulate gastrin and somatostatin secretion and H+-K+-ATPase activity in pigs through calcium-sensing receptor. Gen Comp Endocrinol 1(267):1\u20138. https:\/\/doi.org\/10.1016\/j.ygcen.2018.05.022","journal-title":"Gen Comp Endocrinol"},{"issue":"8","key":"3850_CR56","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/(SICI)1099-081X(1998110)19:8<493::AID-BDD129>3.0.CO;2-Z","volume":"19","author":"KS Han","year":"1998","unstructured":"Han KS, Kim YG, Yoo JK, Lee JW, Lee MG (1998) Pharmacokinetics of a new reversible proton pump inhibitor, YH1885, after intravenous and oral administrations to rats and dogs: hepatic first-pass effect in rats. Biopharm Drug Dispos 19(8):493\u2013500","journal-title":"Biopharm Drug Dispos"},{"key":"3850_CR57","doi-asserted-by":"publisher","DOI":"10.2174\/2589977515666230428140741","author":"AH Anik","year":"2023","unstructured":"Anik AH, Proma FA, Saha P, Sarker S (2023) Tegoprazan as a new remedy for gastrointestinal diseases in comparison with its therapeutic predecessors: a mini-review. Curr Drug Res Rev. https:\/\/doi.org\/10.2174\/2589977515666230428140741","journal-title":"Curr Drug Res Rev"},{"issue":"1","key":"3850_CR58","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/SGA.0000000000000359","volume":"42","author":"J Chen","year":"2019","unstructured":"Chen J, P., B. (2019) Gastroesophageal reflux disease: pathophysiology, diagnosis, and treatment. Gastroenterol Nurs 42(1):20\u201328. https:\/\/doi.org\/10.1097\/SGA.0000000000000359","journal-title":"Gastroenterol Nurs"},{"issue":"1","key":"3850_CR59","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nyas.14501","volume":"1486","author":"P Sharma","year":"2021","unstructured":"Sharma P, R Y (2021) Pathophysiology and treatment options for gastroesophageal reflux disease: looking beyond acid. Ann N Y Acad Sci 1486(1):3\u201314. https:\/\/doi.org\/10.1111\/nyas.14501","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"3850_CR60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1365-2036.2007.03350.x","volume":"26","author":"H Miwa","year":"2007","unstructured":"Miwa H, Sasaki M, Furuta T, Koike T, Habu Y, M. I., Y Fujiwara, T Wada, A Nagahara, M Hongo, T Chiba, Y Kinoshita. (2007) Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther 26(1):69\u201377. https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03350.x","journal-title":"Aliment Pharmacol Ther"},{"key":"3850_CR61","doi-asserted-by":"publisher","unstructured":"Hanxue Zheng, Shunqi Yuan, & Liu, J. (2024). Efficacy and safety of tegoprazan in the treatment of gastroesophageal reflux disease: a protocol for meta-analysis and systematic review. PLOS ONE, 19(5). https:\/\/doi.org\/10.1371\/journal","DOI":"10.1371\/journal"},{"issue":"4","key":"3850_CR62","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/apt.16477","volume":"54","author":"SH Kim","year":"2021","unstructured":"Kim SH, Cho KB, Chun HJ, Lee SW (2021) Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease. Aliment Pharmacol Ther 54(4):402\u2013411. https:\/\/doi.org\/10.1111\/apt.16477","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"3850_CR63","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12876-024-03297-6","volume":"24","author":"C Xue","year":"2024","unstructured":"Xue C, Yuhan Du, Yang H, Huixin Jin YZ, Ren B, Dong Z (2024) Evaluating vonoprazan and tegoprazan for gastroesophageal reflux disease treatment in Chinese HEALTHCARE: an EVIDEM framework analysis. BMC Gastroenterol 24(1):208. https:\/\/doi.org\/10.1186\/s12876-024-03297-6","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"3850_CR64","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.14309\/ajg.0000000000001735","volume":"117","author":"Loren Laine","year":"2022","unstructured":"Laine Loren, Sharma Prateek, Mulford Darcy J, Hunt Barbara, Leifke Eckhard, Smith Neila, Howden CW (2022) Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in US subjects. Am J Gastroenterol 117(7):1158\u20131161. https:\/\/doi.org\/10.14309\/ajg.0000000000001735","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"3850_CR65","doi-asserted-by":"publisher","first-page":"92","DOI":"10.5009\/gnl220050","volume":"17","author":"S Han","year":"2023","unstructured":"Han S, Choi HY, Kim YH, Choi SeungChan, Kim S (2023) Comparison of pharmacodynamics between tegoprazan and dexlansoprazole regarding nocturnal acid breakthrough: a randomized crossover study. Gut Liver 17(4):92\u201399. https:\/\/doi.org\/10.5009\/gnl220050","journal-title":"Gut Liver"},{"issue":"7","key":"3850_CR66","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1111\/bcp.15268","volume":"88","author":"E Yang","year":"2022","unstructured":"Yang E, Kim S, Kim B, Kim B, Kim Y, Park SS, Song GS, Yu KS, Jang IJ, S., L. (2022) Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. Br J Clin Pharmacol 88(7):3288\u20133296. https:\/\/doi.org\/10.1111\/bcp.15268","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3850_CR67","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s12029-020-00518-5","volume":"52","author":"A M","year":"2021","unstructured":"M A (2021) Molecular mechanism of Helicobacter pylori-induced gastric cancer. J Gastrointest Cancer 52(1):23\u201330. https:\/\/doi.org\/10.1007\/s12029-020-00518-5","journal-title":"J Gastrointest Cancer"},{"key":"3850_CR68","doi-asserted-by":"publisher","unstructured":"Wang F, Meng W, Wang B, & L, Q. (2014). Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett, 345(2). https:\/\/doi.org\/10.1016\/j.canlet.2013.08.016","DOI":"10.1016\/j.canlet.2013.08.016"},{"key":"3850_CR69","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","volume":"71","author":"Peter Malfertheiner","year":"2022","unstructured":"Malfertheiner Peter, Megraud Francis, Rokkas T (2022) Management of Helicobacter pylori infection: the maastricht vi\/florence consensus report. Gut 71:1724\u20131762. https:\/\/doi.org\/10.1136\/gutjnl-2022-327745","journal-title":"Gut"},{"key":"3850_CR70","doi-asserted-by":"publisher","unstructured":"Woon Geon Shin, Sang Woo Lee, Gwang Ho Baik, Kyu Chan Huh, Sang In Lee, Jun-Won Chung, & Woon Tae Jung. (2016). Eradication rates of Helicobacter pylori in korea over the past 10 years and correlation of the amount of antibiotics use: Nationwide survey. Helicobacter, 21(4). https:\/\/doi.org\/10.1111\/hel.12279","DOI":"10.1111\/hel.12279"},{"issue":"4","key":"3850_CR71","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3904\/kjim.2023.250","volume":"38","author":"K TH","year":"2023","unstructured":"TH K (2023) Role of potassium-competitive acid blockers in eradication of Helicobacter pylori infection. Korean J Intern Med 38(4):451\u2013453. https:\/\/doi.org\/10.3904\/kjim.2023.250","journal-title":"Korean J Intern Med"},{"issue":"3","key":"3850_CR72","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000504939","volume":"102","author":"S Shinozaki","year":"2021","unstructured":"Shinozaki S, Kobayashi Y, H, O. (2021) Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: systematic review and meta-analysis. Digestion 102(3):319\u2013325. https:\/\/doi.org\/10.1159\/000504939","journal-title":"Digestion"},{"issue":"2","key":"3850_CR73","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/apt.14130","volume":"46","author":"YS Jung","year":"2017","unstructured":"Jung YS, Kim EH, Park CH (2017) Systematic review with meta analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther 46(2):106\u2013114. https:\/\/doi.org\/10.1111\/apt.14130","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"3850_CR74","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1111\/jgh.15939","volume":"37","author":"YS Jung","year":"2022","unstructured":"Jung YS, Kim S, Kim H-Y, Noh SJ, Park JH, Park CH (2022) 7-day versus 14-day tegoprazan-based triple therapy to treat Helicobacter pylori infection: real-world evidence. J Gastroenterol Hepatol 37(10):1911\u20131918. https:\/\/doi.org\/10.1111\/jgh.15939","journal-title":"J Gastroenterol Hepatol"},{"issue":"11","key":"3850_CR75","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.3390\/jpm12111918","volume":"12","author":"CH Park","year":"2022","unstructured":"Park CH, Song MJ, Jung BW (2022) Comparative efficacy of 14-day tegoprazan-based triple vs 10-day tegoprazan-based concomitant therapy for Helicobacter pylori eradication. J Pers Med 12(11):1918. https:\/\/doi.org\/10.3390\/jpm12111918","journal-title":"J Pers Med"},{"issue":"11","key":"3850_CR76","doi-asserted-by":"publisher","first-page":"e00632","DOI":"10.14309\/ctg.0000000000000632","volume":"14","author":"CH Park","year":"2023","unstructured":"Park CH, Park JH, YS J (2023) Comparative efficacy of tegoprazan vs esomeprazole\/sodium bicarbonate for the treatment of Helicobacter pylori infection. Clin Transl Gastroenterol 14(11):e00632. https:\/\/doi.org\/10.14309\/ctg.0000000000000632","journal-title":"Clin Transl Gastroenterol"},{"issue":"5","key":"3850_CR77","doi-asserted-by":"publisher","first-page":"711","DOI":"10.5009\/gnl220218","volume":"17","author":"YS Jung","year":"2023","unstructured":"Jung YS, Kim S, Kim H-Y, Noh SJ, Park JH, Sohn CI, Park CH (2023) Efficacy and tolerability of 14-day tegoprazan- versus rabeprazole-based triple therapy for eradication of Helicobacter pylori: a real-world evidence study. Gut Liver 17(5):711\u2013721. https:\/\/doi.org\/10.5009\/gnl220218","journal-title":"Gut Liver"},{"issue":"4","key":"3850_CR78","doi-asserted-by":"publisher","first-page":"535","DOI":"10.5009\/gnl220055","volume":"16","author":"YJ Choi","year":"2022","unstructured":"Choi YJ, Lee YC, Kim JM, Kim JI, Moon JS, Lim YJ, Baik GH (2022) Triple therapy-based on tegoprazan, a new potassium-competitive acid blocker, for first-line treatment of Helicobacter pylori infection: a randomized, double-blind, phase III, clinical trial. Gut Liver 16(4):535\u2013546. https:\/\/doi.org\/10.5009\/gnl220055","journal-title":"Gut Liver"},{"key":"3850_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14787210.2024.2329251","volume":"13","author":"J-H Cho","year":"2024","unstructured":"Cho J-H (2024) Bismuth add-on improves the efficacy of 2-week tegoprazan-based triple therapy for first-line Helicobacter pylori eradication: a real-world evidence study. Expert Rev Anti Infect Ther 13:1\u20137. https:\/\/doi.org\/10.1080\/14787210.2024.2329251","journal-title":"Expert Rev Anti Infect Ther"},{"key":"3850_CR80","doi-asserted-by":"publisher","unstructured":"Kim JS, Ko W, Chung JW, TH K (2023) Efficacy of tegoprazan-based bismuth quadruple therapy compared with bismuth quadruple therapy for Helicobacter pylori infection: a randomized, double-blind, active-controlled study. Helicobacter 28(3). https:\/\/doi.org\/10.1111\/hel.12977","DOI":"10.1111\/hel.12977"},{"issue":"5","key":"3850_CR81","doi-asserted-by":"publisher","first-page":"668","DOI":"10.5009\/gnl230338","volume":"17","author":"C HH","year":"2023","unstructured":"HH C (2023) Is tegoprazan-based triple therapy effective in regions with high rates of clarithromycin resistance? Gut Liver 17(5):668\u2013669. https:\/\/doi.org\/10.5009\/gnl230338","journal-title":"Gut Liver"},{"issue":"1","key":"3850_CR82","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5009\/gnl20247","volume":"15","author":"JW Lee","year":"2021","unstructured":"Lee JW, Kim N, Nam RH, Jeong Eun Yu, Son JH, Lee SM, Lee DH (2021) Efficacy of tegoprazan for improving the susceptibility of antimicrobial agents against antibiotic-resistant Helicobacter pylori. Gut Liver 15(1):53\u201360. https:\/\/doi.org\/10.5009\/gnl20247","journal-title":"Gut Liver"},{"issue":"6","key":"3850_CR83","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/gutjnl-2017-314852","volume":"67","author":"T Kawai","year":"2018","unstructured":"Kawai T, Oda K, Funao N, Nishimura A, Matsumoto Y, Mizokami Y, Ashida K, Sugano K (2018) Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut 67(6):1033\u20131041. https:\/\/doi.org\/10.1136\/gutjnl-2017-314852","journal-title":"Gut"},{"issue":"6","key":"3850_CR84","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1136\/gutjnl-2017-314010","volume":"67","author":"Y Mizokami","year":"2018","unstructured":"Mizokami Y, Oda K, Funao N, Nishimura A, Soen S, Kawai T, Ashida K, Sugano K (2018) Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut 67(6):1042\u20131051. https:\/\/doi.org\/10.1136\/gutjnl-2017-314010","journal-title":"Gut"},{"issue":"1","key":"3850_CR85","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000484217","volume":"97","author":"Y Kojima","year":"2018","unstructured":"Kojima Y, Takeuchi T, Sanomura M, Higashino K, Kojima K, Fukumoto K, Takata K, Hiroki. (2018) Does the novel potassium-competitive acid blocker vonoprazan cause more hypergastrinemia than conventional proton pump inhibitors? A multicenter prospective cross-sectional study Digestion 97(1):70\u201375. https:\/\/doi.org\/10.1159\/000484217","journal-title":"A multicenter prospective cross-sectional study Digestion"},{"issue":"1","key":"3850_CR86","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1572-0241.2007.01544.x","volume":"103","author":"J Dent","year":"2008","unstructured":"Dent J, Kahrilas PJ, Hatlebakk J, Vakil N, Denison H, Franz\u00e9n S, Lundborg P (2008) A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 103(1):20\u201326. https:\/\/doi.org\/10.1111\/j.1572-0241.2007.01544.x","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"3850_CR87","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.cgh.2007.08.014","volume":"5","author":"PJ Kahrilas","year":"2007","unstructured":"Kahrilas PJ, Dent J, Lauritsen K, Malfertheiner P, Denison H, Franz\u00e9n S, Hasselgren G (2007) A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 5(12):1385\u20131391. https:\/\/doi.org\/10.1016\/j.cgh.2007.08.014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"3850_CR88","doi-asserted-by":"publisher","first-page":"1076356","DOI":"10.3389\/fmed.2022.1076356","volume":"11","author":"M-G Kim","year":"2023","unstructured":"Kim M-G, Im Y-J, Lee J-H, Kim E-Y, Yeom SW, Kim JS (2023) Comparison of hepatotoxicity of tegoprazan, a novel potassium-competitive acid blocker, with proton pump inhibitors using real-world data: a nationwide cohort study. Front Med (Lausanne) 11(9):1076356. https:\/\/doi.org\/10.3389\/fmed.2022.1076356","journal-title":"Front Med (Lausanne)"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03850-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03850-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03850-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:28:47Z","timestamp":1757176127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03850-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":88,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3850"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03850-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"12 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}